Invesco QQQ ETF Up 0.15% in Past Five Days, YTD 9.08%: TipRanks

Wednesday, Jul 16, 2025 10:54 am ET1min read

The Invesco QQQ ETF is up 0.15% in the past five days and 9.08% year-to-date. TipRanks' ETF analyst consensus rates QQQ as a Moderate Buy, with an average price target of $596.67 implying a 7.18% upside. The ETF's five holdings with the highest upside potential are AppLovin, Atlassian Corporation, Lululemon Athletica, Diamondback Energy, and Regeneron Pharmaceuticals, while its five holdings with the greatest downside potential are Palantir Technologies, Advanced Micro Devices, Ansys Inc., Texas Instruments, and KLA Corporation. QQQ's Smart Score is seven, indicating likely in-line performance with the market.

The Invesco QQQ ETF (QQQ) experienced a notable decline in the first quarter of 2025, ending its streak of consecutive positive quarterly returns. The ETF, which tracks the Nasdaq-100 Index, fell by 8.11% on a net asset value (NAV) basis, underperforming the S&P 500 Index by 3.84% but outperforming the Russell 1000 Growth Index by 1.86% [1].

The primary detractors to QQQ's performance were its overweight exposure to the Technology sector and lack of exposure to the Financials sector. Seven of the ten Industry Classification Benchmark (ICB) sectors that QQQ has exposure to finished with positive performance for the quarter, with the Technology sector averaging a 58.71% weighting in QQQ and trading lower by 11.76% [1].

Semiconductors, a subsector within Technology, were particularly hard hit, with a decline of 17.53%. This was exacerbated by the release of Chinese startup DeepSeek's AI models, which caused a ripple effect across AI-related stocks. Microsoft and other tech giants saw their data center projects come under scrutiny, leading to further sell-offs [1].

Despite the overall decline, several individual stocks contributed positively to QQQ's performance. Gilead Sciences and Amgen, both Health Care stocks, saw significant gains following their Q4 earnings reports. Gilead's shares jumped by 7.46% on February 12th, while Amgen's shares rebounded after a challenging 2024, driven by a 6.50% gain on February 5th following its earnings release [1].

Netflix also performed well, with a 4.62% gain for Q1. The company reported strong subscriber growth and revenue, with a 16% year-over-year growth in revenue and 102% growth in earnings per share. Netflix's 2025 revenue guidance was also revised upward [1].

Looking ahead, the Invesco QQQ ETF is up 0.15% in the past five days and 9.08% year-to-date. TipRanks' ETF analyst consensus rates QQQ as a Moderate Buy, with an average price target of $596.67, implying a 7.18% upside [2]. The ETF's five holdings with the highest upside potential are AppLovin, Atlassian Corporation, Lululemon Athletica, Diamondback Energy, and Regeneron Pharmaceuticals, while its five holdings with the greatest downside potential are Palantir Technologies, Advanced Micro Devices, Ansys Inc., Texas Instruments, and KLA Corporation. QQQ's Smart Score is seven, indicating likely in-line performance with the market [2].

References:
[1] https://www.invesco.com/qqq-etf/en/etf-insights/qqq-quarterly-outlook.html
[2] https://www.tipranks.com/etf/qqq

Invesco QQQ ETF Up 0.15% in Past Five Days, YTD 9.08%: TipRanks

Comments



Add a public comment...
No comments

No comments yet